Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lotus Books Solid 2008; Still Needs Cash

publication date: Apr 16, 2009

Lotus Pharmaceuticals (路坦制药有限公司) filed its 2008 financial report showing the company’s revenues, which totaled $73.8 million, were up 30% while net income rose 14% to $12.8 million or 27 cents per fully diluted share. The company said it expected to see “steady” growth in 2009. Unfortunately, Lotus ended 2008 with just $1.3 million in cash and working capital of $4.4 million with two big-dollar projects in the works. More details...

Stock Symbol: (OTCBB: LTUS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital